Prestige Biologics Co. Ltd.
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for… Read more
Prestige Biologics Co. Ltd. (334970) - Net Assets
Latest net assets as of September 2025: ₩122.27 Billion KRW
Based on the latest financial reports, Prestige Biologics Co. Ltd. (334970) has net assets worth ₩122.27 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩269.41 Billion) and total liabilities (₩147.13 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩122.27 Billion |
| % of Total Assets | 45.39% |
| Annual Growth Rate | 134.02% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1369.52 |
Prestige Biologics Co. Ltd. - Net Assets Trend (2018–2024)
This chart illustrates how Prestige Biologics Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Prestige Biologics Co. Ltd. (2018–2024)
The table below shows the annual net assets of Prestige Biologics Co. Ltd. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩135.20 Billion | +88.62% |
| 2023-12-31 | ₩71.68 Billion | -39.05% |
| 2022-12-31 | ₩117.61 Billion | +10.09% |
| 2021-12-31 | ₩106.83 Billion | +7744.85% |
| 2020-12-31 | ₩-1.40 Billion | -104.84% |
| 2019-12-31 | ₩28.85 Billion | +3408.85% |
| 2018-12-31 | ₩822.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Prestige Biologics Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21700919347000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩381.11 Billion | 281.88% |
| Total Equity | ₩135.20 Billion | 100.00% |
Prestige Biologics Co. Ltd. Competitors by Market Cap
The table below lists competitors of Prestige Biologics Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Phinergy Ltd
PINK:PHNGF
|
$35.91 Million |
|
Kumkang Kind Co Ltd
KO:014285
|
$35.92 Million |
|
LEE S PHARMACEUTIC.HD-05
F:L1PA
|
$35.92 Million |
|
Professional Computer Technology Ltd
TWO:6270
|
$35.93 Million |
|
Nilörngruppen AB
PINK:NLLGF
|
$35.90 Million |
|
BROOGE ENERGY DL-0001
F:3SF
|
$35.90 Million |
|
Challenger Gold Limited
PINK:CLLEF
|
$35.89 Million |
|
Onyx Healthcare Inc.
TWO:6569
|
$35.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prestige Biologics Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 71,682,122,400 to 135,203,347,280, a change of 63,521,224,880 (88.6%).
- Net loss of 27,469,488,620 reduced equity.
- New share issuances of 91,041,899,200 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-27.47 Billion | -20.32% |
| Share Issuances | ₩91.04 Billion | +67.34% |
| Other Changes | ₩-51.19 Million | -0.04% |
| Total Change | ₩- | 88.62% |
Book Value vs Market Value Analysis
This analysis compares Prestige Biologics Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.49x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 111.80x to 1.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ₩23.21 | ₩2595.00 | x |
| 2019-12-31 | ₩814.45 | ₩2595.00 | x |
| 2020-12-31 | ₩-39.45 | ₩2595.00 | x |
| 2021-12-31 | ₩2263.08 | ₩2595.00 | x |
| 2022-12-31 | ₩1924.65 | ₩2595.00 | x |
| 2023-12-31 | ₩1165.54 | ₩2595.00 | x |
| 2024-12-31 | ₩1738.89 | ₩2595.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prestige Biologics Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -219.17%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 2.00x
- Recent ROE (-20.32%) is above the historical average (-498.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -3273.07% | 0.00% | 0.00x | 89.00x | ₩-26.99 Billion |
| 2019 | -76.46% | -11938.78% | 0.00x | 2.50x | ₩-24.94 Billion |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-30.89 Billion |
| 2021 | -36.86% | -1220.33% | 0.02x | 1.94x | ₩-50.06 Billion |
| 2022 | -42.27% | -319406.80% | 0.00x | 2.19x | ₩-61.48 Billion |
| 2023 | -40.98% | -1354.23% | 0.01x | 4.04x | ₩-36.54 Billion |
| 2024 | -20.32% | -219.17% | 0.05x | 2.00x | ₩-40.99 Billion |
Industry Comparison
This section compares Prestige Biologics Co. Ltd.'s net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $101,132,182,174
- Average return on equity (ROE) among peers: -1.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prestige Biologics Co. Ltd. (334970) | ₩122.27 Billion | -3273.07% | 1.20x | $35.91 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $186.63 Billion | -0.52% | 0.70x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $85.65 Billion | 17.63% | 0.55x | $58.41 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $38.30 Million |
| Sam-A Pharm. Co. Ltd (009300) | $200.47 Billion | 10.66% | 0.15x | $20.99 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $262.19 Billion | 4.75% | 0.11x | $50.15 Million |
| WooGene B&G Co. Ltd (018620) | $23.04 Billion | -18.19% | 1.63x | $10.29 Million |
| Oscotec Inc (039200) | $26.33 Billion | -13.85% | 0.55x | $962.14 Million |
| EstechPharma Co. Ltd (041910) | $67.96 Billion | 5.45% | 0.54x | $53.07 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $241.35 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $31.66 Billion | 7.06% | 0.46x | $20.53 Million |